Carboplatin Plus Pemetrexed as First-line Treatment of Patients With Malignant Pleural Mesothelioma: A Phase II Study

Katirtzoglou, Nikolaos; Gkiozos, Ioannis; Makrilia, Nektaria; Tsaroucha, Emily; Rapti, Aggeliki; Stratakos, Grigorios; Fountzilas, George; Syrigos, Konstantinos

doi:10.3816/clc.2010.n.005

Cited by 63 publications

(35 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Epitheloid histologic type predicted for longer PFS and survival, a finding reported in several previous trials and reviews [48][49][50]. The fact that the stage of the disease was of no prognostic significance may be partially attributable to the diagnostic process: during the trial period, PET-CT was not available and MRI was only rarely used, as its results would have no impact for treatment.…”

Section: Discussionmentioning

confidence: 85%

A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma

et al. 2012

View full text Add to dashboard Cite

After a favorable experience with gemcitabine at a low dose in a prolonged infusion in combination with cisplatin for advanced non-small-cell lung cancer, here, we present the results from a phase II trial for patients with malignant pleural mesothelioma. Eligible patients had biopsy-proven malignant pleural mesothelioma, were chemo-naive, Eastern Cooperative Oncology Group performance status 0-2, had normal hematopoietic liver and renal function, and gave informed consent. Treatment consisted of gemcitabine 250 mg/m in a 6-h infusion on days 1 and 8 and cisplatin at 75 mg/m on day 2 of a 3-week cycle for four cycles, followed by two additional cycles without cisplatin. Seventy-eight patients (58 men, 20 women; age 33-82 years, median 58) were recruited into the trial. The histologic types were as follows: epitheloid 56 (71.8%); four sarcomatoid (5.1%); mixed 15 (19.2%); and mesothelioma, three not otherwise specified (3.8%). Grades 3-4 toxicity included two (2.6%) patients with anemia, 18 (23.1%) with neutropenia, and one with nausea/vomiting. Reversible thrombocytosis with platelets over 1000-10/l was recorded in 10 (12.8%) patients and grade 2 alopecia in 60 (76.9%). Four (5.1%) patients showed a complete response and 35 (44.9%) showed a partial response with a response rate of 39/78 (50%). Minimal response or stable disease was seen in 35 (44.9%), whereas only four (5.1%) patients progressed during treatment. Most patients reported symptomatic improvement with a higher or a stable quality of life score in 70 (89.7%) cases. The median progression-free survival was 8.0 months (confidence interval 6.9-9.0). The median overall survival was 17.0 months (confidence interval 14.7-19.2). One-year, two-year, and three-year survival rates were 67.3, 32.7, and 19.8%, respectively. Epitheloid histological type was the only statistically significant favorable prognostic factor for progression-free survival and overall survival. Because of the acceptable toxicity, remarkable activity, and reasonable cost, this treatment should be further explored.

show abstract

Section: Discussionmentioning

confidence: 85%

A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…14 months. 53,54 This may be due to the subtle clinical course of the disease. However, what makes MPM a fatal disease is the lack of effective therapeutic options available.…”

Section: Butein Affects the Resistance Of Mpm Cells To Pemetrexedmentioning

confidence: 99%

Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells

et al. 2012

View full text Add to dashboard Cite

“…Recent phase II trials using pemetrexed-platinum doublets have been even more encouraging, consistently showing median survivals of 14-15 months for advanced-stage patients [9,10]. These results are close to those obtained with EPP-based multimodality treatment in selected early-stage MPM patients.…”

mentioning

confidence: 57%

Pemetrexed re-challenge in pleural malignant mesothelioma: An option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?

Zalcman

Lechapt‐Zalcman

2011

Lung Cancer

View full text Add to dashboard Cite

Carboplatin Plus Pemetrexed as First-line Treatment of Patients With Malignant Pleural Mesothelioma: A Phase II Study

Cited by 63 publications

References 31 publications

A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma

A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma

Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells

Pemetrexed re-challenge in pleural malignant mesothelioma: An option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?

Contact Info

Product

Resources

About